import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "kpv-peptide-anti-inflammatory-research-guide",
  title: "KPV Peptide: Anti-Inflammatory Research Guide (2026)",
  description:
    "KPV (Lys-Pro-Val) is a tripeptide derived from alpha-MSH with potent anti-inflammatory properties studied in gut, skin, and systemic inflammation models. This guide covers its mechanisms, key research, and sourcing.",
  category: "Compound Profiles",
  readMinutes: 9,
  publishedAt: "2026-06-17",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "KPV is a C-terminal tripeptide fragment of alpha-melanocyte stimulating hormone (α-MSH), comprising the amino acid sequence Lysine-Proline-Valine. Despite its small size — just three amino acids — it has generated substantial preclinical research interest for its anti-inflammatory activity across gut, skin, and systemic inflammatory models.",
    },
    {
      type: "callout",
      text: "Note: KPV is sold for research purposes only. It is not approved for human use, therapeutic application, or clinical diagnosis. All references to protocols and mechanisms below are drawn from preclinical animal studies.",
    },
    {
      type: "heading",
      text: "What Is KPV?",
    },
    {
      type: "paragraph",
      text: "Alpha-MSH is a pleiotropic neuropeptide with well-documented anti-inflammatory activity mediated primarily through melanocortin receptors (MC1R, MC3R). Researchers identified that the C-terminal tripeptide fragment — KPV — retains much of this anti-inflammatory activity, and notably, can act through both receptor-dependent and receptor-independent mechanisms.",
    },
    {
      type: "list",
      items: [
        "Molecular formula: C₁₆H₃₁N₅O₄",
        "Molecular weight: ~357 Da",
        "Derived from: alpha-MSH C-terminal sequence",
        "Administration routes studied: subcutaneous, oral, topical, intranasal",
        "CAS Number: 69661-02-5",
      ],
    },
    {
      type: "heading",
      text: "Mechanism of Action",
    },
    {
      type: "paragraph",
      text: "KPV's anti-inflammatory activity has been investigated through several molecular pathways in preclinical studies.",
    },
    {
      type: "subheading",
      text: "NF-κB Inhibition",
    },
    {
      type: "paragraph",
      text: "One of the most replicated findings in KPV research is its ability to inhibit NF-κB (nuclear factor kappa B) signaling. NF-κB is a master transcription factor controlling expression of pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β. In cell culture models, KPV has been shown to reduce nuclear translocation of NF-κB subunits, blunting downstream inflammatory gene expression.",
    },
    {
      type: "subheading",
      text: "Melanocortin Receptor Engagement",
    },
    {
      type: "paragraph",
      text: "KPV binds melanocortin receptors, particularly MC1R expressed on immune cells and MC3R in the central nervous system. Receptor activation triggers cAMP-mediated signaling cascades that modulate macrophage polarization toward an anti-inflammatory (M2) phenotype in preclinical models.",
    },
    {
      type: "subheading",
      text: "Intracellular Entry",
    },
    {
      type: "paragraph",
      text: "Uniquely among small peptides, KPV has been shown in some studies to penetrate cell membranes and exert intracellular anti-inflammatory effects independent of surface receptor binding. This property has made it particularly interesting to researchers studying gut epithelial inflammation, where intracellular cytokine signaling is a key disease driver.",
    },
    {
      type: "heading",
      text: "Key Research Areas",
    },
    {
      type: "subheading",
      text: "Inflammatory Bowel Disease (IBD) Models",
    },
    {
      type: "paragraph",
      text: "The most extensively studied application of KPV in preclinical literature is inflammatory bowel disease. Studies using DSS (dextran sodium sulfate) colitis models in mice have demonstrated that orally administered KPV reduces colon inflammation markers including myeloperoxidase activity, mucosal damage scores, and pro-inflammatory cytokine levels. Researchers have speculated that KPV's resistance to GI enzymatic degradation may allow meaningful luminal activity.",
    },
    {
      type: "subheading",
      text: "Skin Inflammation",
    },
    {
      type: "paragraph",
      text: "Given α-MSH's known role in skin biology, KPV has been examined in models of contact hypersensitivity and inflammatory skin conditions. Topical KPV formulations have shown reduction in edema, immune cell infiltration, and cytokine expression in murine models of dermatitis.",
    },
    {
      type: "subheading",
      text: "Systemic Inflammation and Sepsis",
    },
    {
      type: "paragraph",
      text: "In LPS (lipopolysaccharide) challenge models — a standard preclinical model of systemic inflammatory response — KPV administration has been associated with reduced circulating TNF-α and IL-6 levels and improved survival rates in some rodent studies. These findings have driven interest in its potential anti-cytokine-storm mechanisms.",
    },
    {
      type: "heading",
      text: "KPV vs. BPC-157: Anti-Inflammatory Comparison",
    },
    {
      type: "table",
      headers: ["Property", "KPV", "BPC-157"],
      rows: [
        ["Size", "Tripeptide (3 AA)", "Pentadecapeptide (15 AA)"],
        ["Primary pathway", "NF-κB / MC receptors", "NO system / VEGF / FAK-paxillin"],
        ["Gut research", "IBD, colitis models", "Gut integrity, leaky gut"],
        ["Skin research", "Dermatitis, hypersensitivity", "Wound healing, angiogenesis"],
        ["Oral bioavailability", "Studied, notable stability", "Studied, notable stability"],
        ["Systemic effects", "Cytokine modulation", "Multi-tissue repair"],
      ],
    },
    {
      type: "heading",
      text: "Research Protocols and Dosing (Preclinical)",
    },
    {
      type: "paragraph",
      text: "The following dosing information is derived exclusively from animal studies and is presented for educational purposes only. It does not constitute medical advice.",
    },
    {
      type: "list",
      items: [
        "Rodent colitis models: 0.1–1 mg/kg administered orally or subcutaneously",
        "Skin inflammation models: topical formulations at varying concentrations (0.01%–1%)",
        "Systemic inflammation (LPS) models: 50–200 µg/kg IP or SC",
        "Research cycle durations studied: typically acute (single dose) to 2-week protocols",
      ],
    },
    {
      type: "heading",
      text: "Sourcing and Quality Considerations",
    },
    {
      type: "paragraph",
      text: "Because KPV is a small, relatively simple tripeptide, it is susceptible to counterfeit production using inactive substitutes or low-purity synthesis. Researchers sourcing KPV should prioritize vendors providing:",
    },
    {
      type: "list",
      items: [
        "HPLC purity certificates showing ≥98% purity",
        "Mass spectrometry confirmation of correct molecular weight (357 Da)",
        "LAL endotoxin testing to confirm <1 EU/mg",
        "Proper lyophilization and cold-chain handling documentation",
        "Batch-specific CoA available for download",
      ],
    },
    {
      type: "paragraph",
      text: "Nexphoria provides full batch-level HPLC and MS documentation for all KPV products, with cold-chain shipping as standard. Each batch includes a downloadable CoA with purity, identity, and endotoxin data.",
    },
    {
      type: "heading",
      text: "Storage and Reconstitution",
    },
    {
      type: "list",
      items: [
        "Lyophilized powder: store at -20°C, protected from light",
        "Reconstituted solution: store at 4°C, use within 4 weeks",
        "Recommended diluent: bacteriostatic water or sterile saline",
        "Avoid repeated freeze-thaw cycles after reconstitution",
        "KPV is water-soluble; does not require acetic acid for reconstitution",
      ],
    },
    {
      type: "heading",
      text: "Current Research Landscape",
    },
    {
      type: "paragraph",
      text: "As of 2026, KPV remains an active area of preclinical investigation, particularly in the context of IBD pathophysiology and oral peptide delivery. Researchers have explored nanoparticle and hydrogel formulations to enhance targeted colonic delivery. It is increasingly studied in combination with other anti-inflammatory peptides — most commonly BPC-157 and thymosin α1 — for multi-target gut inflammation protocols.",
    },
    {
      type: "heading",
      text: "Frequently Asked Questions",
    },
    {
      type: "subheading",
      text: "Is KPV the same as BPC-157?",
    },
    {
      type: "paragraph",
      text: "No. KPV is a tripeptide derived from α-MSH that works primarily through NF-κB inhibition and melanocortin receptors. BPC-157 is a 15-amino acid peptide with distinct mechanisms centered on nitric oxide and growth factor pathways. They address overlapping but distinct aspects of inflammation.",
    },
    {
      type: "subheading",
      text: "Can KPV be taken orally?",
    },
    {
      type: "paragraph",
      text: "Animal studies have tested oral administration with positive results, suggesting notable stability in GI environments. However, oral bioavailability in humans has not been established in clinical trials.",
    },
    {
      type: "subheading",
      text: "What makes KPV unique among anti-inflammatory peptides?",
    },
    {
      type: "paragraph",
      text: "Its intracellular entry capability and receptor-independent anti-inflammatory activity distinguish KPV from most other peptides, which rely on extracellular receptor engagement. This property has made it particularly interesting for gut mucosa research.",
    },
    {
      type: "divider",
    },
    {
      type: "disclaimer",
      text: "This article is for informational and educational purposes only. KPV is a research compound not approved for human use by the FDA or any other regulatory body. Nothing in this article constitutes medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before beginning any supplement or peptide protocol.",
    },
  ],
};
